[HTML][HTML] Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781
J Tepper, MJ Krasna, D Niedzwiecki… - Journal of clinical …, 2008 - ncbi.nlm.nih.gov
Purpose The primary treatment modality for patients with carcinoma of the esophagus or
gastroesophageal junction has been surgery, although primary radiation therapy with …
gastroesophageal junction has been surgery, although primary radiation therapy with …
Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells
…, S Pruitt, J Madden, D Coleman, D Niedzwiecki… - Cancer research, 2003 - AACR
Autologous dendritic cells transfected with total renal tumor RNA have been shown to be
potent stimulators of CTLs and antitumor immunity in vitro. A Phase I trial was conducted to …
potent stimulators of CTLs and antitumor immunity in vitro. A Phase I trial was conducted to …
[HTML][HTML] Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and …
HL Kindler, D Niedzwiecki, D Hollis… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
Purpose The combination of gemcitabine plus bevacizumab produced a 21% response rate
and a median survival of 8.8 months in a multicenter phase II trial in patients with metastatic …
and a median survival of 8.8 months in a multicenter phase II trial in patients with metastatic …
[HTML][HTML] Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors
…, CD Lallas, P Dahm, D Niedzwiecki… - The Journal of …, 2002 - Am Soc Clin Investig
Autologous dendritic cells (DCs) transfected with mRNA encoding prostate-specific antigen (PSA)
are able to stimulate potent, T cell–mediated antitumor immune responses in vitro. A …
are able to stimulate potent, T cell–mediated antitumor immune responses in vitro. A …
Impact of number of nodes retrieved on outcome in patients with rectal cancer
JE Tepper, MJ O'connell, D Niedzwiecki… - Journal of clinical …, 2001 - ascopubs.org
PURPOSE: We postulated that the pathologic evaluation of the lymph nodes of surgical
specimens from patients with rectal cancer can have a substantial impact on time to relapse and …
specimens from patients with rectal cancer can have a substantial impact on time to relapse and …
[HTML][HTML] Duration of adjuvant chemotherapy for stage III colon cancer
…, JP Meyers, LA Renfro, D Niedzwiecki… - … England Journal of …, 2018 - Mass Medical Soc
Background Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine
has been standard adjuvant therapy in patients with stage III colon cancer. However, …
has been standard adjuvant therapy in patients with stage III colon cancer. However, …
Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer …
AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti… - Jama, 2017 - jamanetwork.com
Importance Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs
provides clinical benefit to patients with advanced or metastatic colorectal cancer, but the …
provides clinical benefit to patients with advanced or metastatic colorectal cancer, but the …
[PDF][PDF] Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB …
LB Saltz, D Niedzwiecki, D Hollis… - Journal of Clinical …, 2007 - academia.edu
Purpose Randomized studies have shown that irinotecan (CPT-11) extends survival in
metastatic colorectal cancer patients when administered in second-line and when added to …
metastatic colorectal cancer patients when administered in second-line and when added to …
[PDF][PDF] Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future …
…, SJ Lee, JAW Chapman, D Niedzwiecki… - Journal of Clinical …, 2008 - academia.edu
Purpose Objective tumor response rates observed in phase II trials for metastatic melanoma
have historically not provided a reliable indicator of meaningful survival benefits. To …
have historically not provided a reliable indicator of meaningful survival benefits. To …
Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer
JA Meyerhardt, D Niedzwiecki, D Hollis, LB Saltz… - Jama, 2007 - jamanetwork.com
ContextDietary factors have been associated with the risk of developing colon cancer but
the influence of diet on patients with established disease is unknown.ObjectiveTo determine …
the influence of diet on patients with established disease is unknown.ObjectiveTo determine …